Pfizer-BioNTech vaccine induces the production of cross-reactive antibodies against Trypanosoma cruzi proteins: A preliminary study.

López-Monteon AracelyAreli Eunice Balderas-CaballeroJorge Alberto Domínguez-GuillénHéctor Romero-RamírezShantal Lizbeth Baltierra-UribeRamos-Ligonio Angel

Published in: Tropical medicine & international health : TM & IH (2023)

The data suggest that people convalescing from COVID-19 and those who received the Pfizer-BioNTech vaccine exhibit cross-reactive antibodies against T. cruzi antigens in ELISA assays.

Keyphrases

trypanosoma cruzi
coronavirus disease
sars cov
electronic health record
high throughput
dendritic cells
big data
deep learning
artificial intelligence